by Enligt en artikel i The Exposé från 2022-02-13, har ett brittiskt laboratorium analyserat injektionsampuller från AstraZeneca, Moderna och Pfizer och funnit att samtliga innehåller olika varianter av graphene.
”The Covid-19 vaccines have been forensically examined in the United Kingdom and a laboratory report confirms they contain graphene nanomaterials that can penetrate the body’s natural barriers and damage the central nervous system, and Graphene Oxide which can damage internal organs, destroy blood health, trigger cancer, and cause changes in gene function among a host of other ill effects.”
”The Identified inclusions were:
- Graphene nano ribbons coated with Polyethylene Glycol
- Graphene Composite Form 1.
- Graphene Composite Form 2.
- Microcrystalline Calcite with Carbonaceous inclusions.
- Graphene Nano Form with and without fluorescence
- Graphene nano objects
- Graphene nano scrolls”
AstraZeneca, Moderna och Pfizer har polisanmälts och laboratorierapporten har bifogats anmälan.
”The report titled “Qualitative Evaluation of Inclusions In Moderna, AstraZeneca and Pfizer Covid-19 vaccines” has been presented to the Police involved in the UK Criminal Case, 6029679/21, which is said to provide them with more than enough reasonable suspicion that serious indictable offences have been committed regarding the administration of experimental treatments.
The report contains the toxicology reports of injection vials that have been forensically examined, with findings that provide “more than enough grounds” for the Police to apply for the Police and Criminal Evidence Act 1984 Warrant and seize injection vials for themselves.
The Police will then be able to submit them to a Home Office Laboratory with a view to replicate the findings and will enable them to possess their own hard evidence to support serious indictable offences.
Additionally, the police, in line with the duty of care to the public, have been asked to request the immediate cessation of the experimental treatment rollout.
Källor:
http://ukcitizen2021.org/Case_Briefing_Document_and_lab_report_Ref_AUC_101_Report%20.pdf
